LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Pigment Epithelium-Derived Factor (PEDF) mediates cartilage matrix loss in an age-dependent manner under inflammatory conditions.

    Nakamura, Daisy S / Hollander, Judith M / Uchimura, Tomoya / Nielsen, Heber C / Zeng, Li

    BMC musculoskeletal disorders

    2017  Volume 18, Issue 1, Page(s) 39

    Abstract: Background: Inflammation is a major cause of cartilage destruction and leads to the imbalance of metabolic activities in the arthritic joint. Pigment epithelium-derived factor (PEDF) has been reported to have both pro- and anti-inflammatory activities ... ...

    Abstract Background: Inflammation is a major cause of cartilage destruction and leads to the imbalance of metabolic activities in the arthritic joint. Pigment epithelium-derived factor (PEDF) has been reported to have both pro- and anti-inflammatory activities in various cell types and to be upregulated in the arthritic joint, but its role in joint destruction is unclear. Our aim was to investigate the role of PEDF in cartilage degeneration under inflammatory conditions.
    Methods: PEDF was ectopically expressed in primary human articular chondrocytes, and catabolic gene expression and protein secretion in response to the pro-inflammatory cytokine interleukin 1 beta (IL-1β) were evaluated. Metatarsal bones from PEDF-deficient and wild type mice were cultured in the presence or absence of IL-1β. Cartilage matrix integrity and matrix metalloproteinases MMP-1, MMP-3, and MMP-13 were evaluated. PEDF-deficient and wild type mice were evaluated in the monosodium iodoacetate (MIA) inflammatory joint destruction animal model to determine the role of PEDF in inflammatory arthritis in vivo. Student's t-tests and Mann-Whitney tests were employed where appropriate, for parametric and non-parametric data, respectively.
    Results: We showed that PEDF protein levels were higher in human osteoarthritis samples compared to normal samples. We demonstrated that ectopic PEDF expression in primary human articular chondrocytes exacerbated catabolic gene expression in the presence of IL-1β. In whole bone organ cultures, IL-1β induced MMP-1, MMP-3 and MMP-13 protein production, and caused significant cartilage matrix loss. Interestingly, Toluidine Blue staining showed that PEDF-deficient bones from 29 week old animals, but not 10 week old animals, had reduced matrix loss in response to IL-1β compared to their wild type counterparts. In addition, PEDF-deficiency in 29 week old animals preserved matrix integrity and protected against cell loss in the MIA joint destruction model in vivo.
    Conclusion: We conclude that PEDF exacerbates cartilage degeneration in an age-dependent manner under an inflammatory setting. This is the first study identifying a specific role for PEDF in joint inflammation and highlights the multi-faceted activities of PEDF.
    Language English
    Publishing date 2017-01-25
    Publishing country England
    Document type Journal Article
    ISSN 1471-2474
    ISSN (online) 1471-2474
    DOI 10.1186/s12891-017-1410-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity.

    Uchimura, Tomoya / Nakamura, Daisy S / Link, Eric M / Noguchi, Yoshihiko / Ōmura, Satoshi / Sunazuka, Toshiaki / Greenblatt, David J / Zeng, Li

    Biochemical pharmacology

    2019  Volume 165, Page(s) 79–90

    Abstract: Osteoarthritis (OA) is a prevalent disease characterized by chronic joint degeneration and low-grade localized inflammation. There is no available treatment to delay OA progression. We report that in human primary articular chondrocytes, erythromycin, a ... ...

    Abstract Osteoarthritis (OA) is a prevalent disease characterized by chronic joint degeneration and low-grade localized inflammation. There is no available treatment to delay OA progression. We report that in human primary articular chondrocytes, erythromycin, a well-known macrolide antibiotic, had the ability to inhibit pro-inflammatory cytokine Interleukin 1β (IL-1β)-induced catabolic gene expression and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation. Furthermore, erythromycin inhibited monosodium iodoacetate (MIA)-induced joint inflammation and cartilage matrix destruction in mice, an arthritis model that reflects the inflammatory and cartilage matrix loss aspects of OA. EM900, an erythromycin-derivative lacking antibiotic function, had the same activity as erythromycin in vitro and in vivo, indicating distinct anti-inflammatory and antibiotic properties. Using an antibody against erythromycin, we found erythromycin was present on chondrocytes in a dose-dependent manner. The association of erythromycin with chondrocytes was diminished in ghrelin receptor null chondrocytes, and administration of the ghrelin ligand prevented the association of erythromycin with chondrocytes. Importantly, the anti-inflammatory activity of erythromycin was diminished in ghrelin receptor null chondrocytes. Moreover, erythromycin could not exert its chondroprotective effect in ghrelin receptor null mice, and the loss of ghrelin receptor further augmented joint damage upon MIA-injection. Therefore, our study identified a novel pharmacological mechanism for how erythromycin exerts its chondroprotective effect. This mechanism entails ghrelin receptor signaling, which is necessary for alleviating inflammation and joint destruction.
    MeSH term(s) Animals ; Cells, Cultured ; Chondrocytes/drug effects ; Erythromycin/pharmacology ; Humans ; Inflammation/prevention & control ; Interleukin-1beta/antagonists & inhibitors ; Male ; Mice ; Mice, Inbred C57BL ; NF-kappa B/physiology ; Osteoarthritis/drug therapy ; Receptors, Ghrelin/drug effects ; Receptors, Ghrelin/physiology
    Chemical Substances Interleukin-1beta ; NF-kappa B ; Receptors, Ghrelin ; Erythromycin (63937KV33D)
    Language English
    Publishing date 2019-03-09
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 208787-x
    ISSN 1873-2968 ; 0006-2952
    ISSN (online) 1873-2968
    ISSN 0006-2952
    DOI 10.1016/j.bcp.2019.03.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: An essential role for IGF2 in cartilage development and glucose metabolism during postnatal long bone growth.

    Uchimura, Tomoya / Hollander, Judith M / Nakamura, Daisy S / Liu, Zhiyi / Rosen, Clifford J / Georgakoudi, Irene / Zeng, Li

    Development (Cambridge, England)

    2017  Volume 144, Issue 19, Page(s) 3533–3546

    Abstract: Postnatal bone growth involves a dramatic increase in length and girth. Intriguingly, this period of growth is independent of growth hormone and the underlying mechanism is poorly understood. Recently, ... ...

    Abstract Postnatal bone growth involves a dramatic increase in length and girth. Intriguingly, this period of growth is independent of growth hormone and the underlying mechanism is poorly understood. Recently, an
    MeSH term(s) Animals ; Animals, Newborn ; Bone Development/genetics ; Cartilage/embryology ; Cartilage/metabolism ; Cell Differentiation ; Chondrocytes/metabolism ; Chondrocytes/pathology ; Chondrogenesis/genetics ; Gene Expression Regulation, Developmental ; Glucose/metabolism ; Glycolysis ; Growth Plate/metabolism ; Growth Plate/pathology ; Hypertrophy ; Insulin-Like Growth Factor II/metabolism ; Mice ; Models, Biological ; Mutation/genetics ; Organ Culture Techniques ; Phenotype
    Chemical Substances Insulin-Like Growth Factor II (67763-97-7) ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2017-09-29
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 90607-4
    ISSN 1477-9129 ; 0950-1991
    ISSN (online) 1477-9129
    ISSN 0950-1991
    DOI 10.1242/dev.155598
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes.

    Nakamura, Kenta / Neidig, Lauren E / Yang, Xiulan / Weber, Gerhard J / El-Nachef, Danny / Tsuchida, Hiroshi / Dupras, Sarah / Kalucki, Faith A / Jayabalu, Anu / Futakuchi-Tsuchida, Akiko / Nakamura, Daisy S / Marchianò, Silvia / Bertero, Alessandro / Robinson, Melissa R / Cain, Kevin / Whittington, Dale / Tian, Rong / Reinecke, Hans / Pabon, Lil /
    Knollmann, Björn C / Kattman, Steven / Thies, R Scott / MacLellan, W Robb / Murry, Charles E

    Stem cell reports

    2021  Volume 16, Issue 10, Page(s) 2473–2487

    Abstract: Heart failure remains a significant cause of morbidity and mortality following myocardial infarction. Cardiac remuscularization with transplantation of human pluripotent stem cell-derived cardiomyocytes is a promising preclinical therapy to restore ... ...

    Abstract Heart failure remains a significant cause of morbidity and mortality following myocardial infarction. Cardiac remuscularization with transplantation of human pluripotent stem cell-derived cardiomyocytes is a promising preclinical therapy to restore function. Recent large animal data, however, have revealed a significant risk of engraftment arrhythmia (EA). Although transient, the risk posed by EA presents a barrier to clinical translation. We hypothesized that clinically approved antiarrhythmic drugs can prevent EA-related mortality as well as suppress tachycardia and arrhythmia burden. This study uses a porcine model to provide proof-of-concept evidence that a combination of amiodarone and ivabradine can effectively suppress EA. None of the nine treated subjects experienced the primary endpoint of cardiac death, unstable EA, or heart failure compared with five out of eight (62.5%) in the control cohort (hazard ratio = 0.00; 95% confidence interval: 0-0.297; p = 0.002). Pharmacologic treatment of EA may be a viable strategy to improve safety and allow further clinical development of cardiac remuscularization therapy.
    MeSH term(s) Amiodarone/therapeutic use ; Animals ; Anti-Arrhythmia Agents/therapeutic use ; Arrhythmias, Cardiac/drug therapy ; Cell Line ; Cell- and Tissue-Based Therapy/adverse effects ; Disease Models, Animal ; Drug Combinations ; Humans ; Ivabradine/therapeutic use ; Male ; Myocardial Infarction/drug therapy ; Myocytes, Cardiac/transplantation ; Pluripotent Stem Cells/transplantation ; Stem Cell Transplantation/adverse effects ; Swine ; Tachycardia/drug therapy
    Chemical Substances Anti-Arrhythmia Agents ; Drug Combinations ; Ivabradine (3H48L0LPZQ) ; Amiodarone (N3RQ532IUT)
    Language English
    Publishing date 2021-09-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2720528-9
    ISSN 2213-6711 ; 2213-6711
    ISSN (online) 2213-6711
    ISSN 2213-6711
    DOI 10.1016/j.stemcr.2021.08.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Analysis of the trajectory of osteoarthritis development in a mouse model by serial near-infrared fluorescence imaging of matrix metalloproteinase activities.

    Leahy, Averi A / Esfahani, Shadi A / Foote, Andrea T / Hui, Carrie K / Rainbow, Roshni S / Nakamura, Daisy S / Tracey, Brian H / Mahmood, Umar / Zeng, Li

    Arthritis & rheumatology (Hoboken, N.J.)

    2014  Volume 67, Issue 2, Page(s) 442–453

    Abstract: Objective: A major hurdle in osteoarthritis (OA) research is the lack of sensitive detection and monitoring methods. It is hypothesized that proteases, such as matrix metalloproteinases (MMPs), are up-regulated in the early stages of OA development. ... ...

    Abstract Objective: A major hurdle in osteoarthritis (OA) research is the lack of sensitive detection and monitoring methods. It is hypothesized that proteases, such as matrix metalloproteinases (MMPs), are up-regulated in the early stages of OA development. This study was undertaken to investigate if a near-infrared (NIR) fluorescent probe activated by MMPs could visualize in vivo OA progression beginning in the early stages of the disease.
    Methods: Using an MMP-activatable NIR fluorescent probe (MMPSense 680), we assessed the up-regulation of MMP activity in vitro by incubating human chondrocytes with the proinflammatory cytokine interleukin-1β (IL-1β). MMP activity was then evaluated in vivo serially in a mouse model of chronic, injury-induced OA. To track MMP activity over time, mice were imaged 1-8 weeks after OA-inducing surgery. Imaging results were correlated with histologic findings.
    Results: In vitro studies confirmed that NIR fluorescence imaging identified enhanced MMP activity in IL-1β-treated human chondrocytes. In vivo imaging showed significantly higher fluorescence intensity in OA knees compared to sham-operated (control) knees of the same mice. Additionally, the total emitted fluorescence intensity steadily increased over the entire course of OA progression that was examined. NIR fluorescence imaging results correlated with histologic findings, which showed an increase in articular cartilage structural damage over time.
    Conclusion: Imaging of MMP activity in a mouse model of OA provides sensitive and consistent visualization of OA progression, beginning in the early stages of OA. In addition to facilitating the preclinical study of OA modulators, this approach has the potential for future translation to humans.
    MeSH term(s) Animals ; Cells, Cultured ; Cellular Microenvironment ; Chondrocytes/drug effects ; Chondrocytes/metabolism ; Chondrocytes/pathology ; Disease Models, Animal ; Disease Progression ; In Vitro Techniques ; Interleukin-1beta/pharmacology ; Male ; Matrix Metalloproteinases/metabolism ; Menisci, Tibial/surgery ; Mice ; Mice, Inbred Strains ; Optical Imaging/methods ; Osteoarthritis, Knee/metabolism ; Osteoarthritis, Knee/pathology ; Osteoarthritis, Knee/physiopathology ; Sensitivity and Specificity
    Chemical Substances Interleukin-1beta ; Matrix Metalloproteinases (EC 3.4.24.-)
    Language English
    Publishing date 2014-11-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.38957
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top